Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,262% of patients treated with ianalumab plus eltrombopag achieved sustained platelet response at six months compared to 39% with placebo plus eltrombopag1,2Ianalumab, administered as four once-monthly intravenous doses in the ITP setting, has the potential to reduce the need for chronic treatment and deliver durable disease control in ITPNovartis plans to submit VAYHIT2 data from second-line ITP with results from ongoing first-line ITP trial, VAYHIT1, to health authorities in 2027Basel, December 9, 2025 – Novartis today announced positive results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia...

Digital asset holdings facilitate Exodus’ agreement to acquire W3C OMAHA, Neb., Dec. 09, 2025 (GLOBE NEWSWIRE) — Exodus Movement, Inc. (NYSE American: EXOD) (“Exodus” or “the company”), a leading self-custodial cryptocurrency platform, today announced an update to selected digital asset holdings of Exodus’ corporate treasury, as well as updated user and exchange provider processed volume metrics, as of November 30, 2025: Selected Digital Asset Holdings (Unaudited)Bitcoin (BTC): 1,902 BTC as of November 30, 2025, compared to 2,147 BTC as of October 31, 2025.Of the 1,902 BTC held as of November 30, 2025, 1,116 BTC is pledged as collateral under the Company’s credit facility with Galaxy Digital.Ethereum (ETH): 2,802 ETH as of November 30, 2025 compared to 2,784 as of October 31, 2025.Solana (SOL): 31,050 SOL as of November...

Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a strong foundation for a successful launch of FYB206 Strong early partnering interest underscores industry confidence in Formycon’s biosimilar expertise and development excellence Agreement structure includes in total mid-teens-million-euro upfront and 2025 milestone payments, alongside additional development and regulatory milestones and a mid-double-digit-gross-profit-share upon launch Clinical development phase of FYB206 nearly completed; primary endpoint data expected in the first quarter of 2026PLANEGG-MARTINSRIED, Germany and AHMEDABAD, India, Dec. 09, 2025 (GLOBE NEWSWIRE) — Formycon AG (FSE: FYB, “Formycon”) and Zydus Lifesciences Limited (including its subsidiaries and affiliates, “Zydus”), today...

Progression-free response stayed consistent across age, BMI, and menopausal status in MONALEESA pooled analysis1KISQALI is only CDK4/6i to demonstrate statistically significant overall survival (OS) in MBC across all Phase III trials2-12New NATALEE 5-year sub-analysis data reinforce sustained reduction in distant disease-free survival in broadest population of EBC patients13Basel, December 9, 2025 – Novartis today announced results showing that one in four patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) remained progression-free for four or more years following treatment with Kisqali® (ribociclib) plus endocrine therapy (ET)1. Results were from a pooled, post-hoc exploratory analysis of first-line patients in the MONALEESA trials and will be presented...

Heineken® 0.0 and premium racket brand LÕK announce the first-ever padel racket with a built-in bottle opener and six-pack branded balls.Heineken® 0.0 x LÕK serve up the world’s first padel racket with a built-in bottle openerHeineken® 0.0 and premium racket brand LÕK announce the first-ever padel racket with a built-in bottle opener and six-pack branded balls.Heineken® 0.0 x LÕK serve up the world’s first padel racket with a built-in bottle openerHeineken® 0.0 and premium racket brand LÕK announce the first-ever padel racket with a built-in bottle opener and six-pack branded balls The launch adds to Heineken® 0.0’s expanding presence in padel, adding to its new global partnerships with Playtomic and Premier PadelAMSTERDAM, Dec. 09, 2025 (GLOBE NEWSWIRE) — Heineken® 0.0 and LÕK today announce the Special...

NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today released a year-end Letter from Chief Executive Officer Jody Aufrichtig, summarizing the Company’s 2025 achievements and outlining its strategic vision for 2026. In his year-end letter to shareholders, Aufrichtig described 2025 as a “turning point” in which Psyence BioMed delivered clinical execution, strengthened global manufacturing ties, and positioned itself at the forefront of the convergence between nature-derived psychedelic therapeutics and longevity science. “We recruited and dosed our first patients in a Phase IIb study. Through a further investment in PsyLabs we secured our psychedelic...

SUDBURY, Ontario, Dec. 09, 2025 (GLOBE NEWSWIRE) — Magna Mining Inc. (TSXV: NICU) (OTCQX: MGMNF) (FSE: 8YD) (“Magna” or the “Company”) is pleased to provide an update on exploration activities and assay results from ongoing exploration at the past-producing Levack Mine, located in the North Range of the Sudbury Basin, northeastern Ontario, Canada (Figure 1). Today’s release incorporates the results from four diamond drill holes which tested the R2 target, with all four holes intersecting multiple veins containing high grade copper (“Cu”) and precious metals, including platinum (“Pt”), palladium (“Pd”), gold (“Au), and silver (“Ag”). Mineralization within the R2 target area has now been intersected over a vertical extent of greater than 200 metres and remains open up-dip towards the No. 3 Footwall Zone and at depth and to the west...

CASTELLUM, INC.’s CEO PROVIDES ITS SHAREHOLDERS A CORPORATE UPDATECastellum, Inc. (NYSE-American: CTM) (the “Company”, “CTM” and “Castellum”), a cybersecurity, electronic warfare, and software services and solutions company focused on the federal government, releases this letter to shareholders from Chief Executive Officer (“CEO”), Glen Ives – www.castellumus.comVIENNA, Va., Dec. 09, 2025 (GLOBE NEWSWIRE) — Castellum, Inc. (NYSE-American: CTM) (the “Company”, “CTM” and “Castellum”), a cybersecurity, electronic warfare, and software services and solutions company focused on the federal government, releases this letter to shareholders from Chief Executive Officer (“CEO”), Glen Ives. Dear Fellow Shareholders: As we approach the end of this calendar year, I thought it timely to provide you with a brief update to my July...

WATERLOO, Ontario and ATLANTA, Ga., Dec. 09, 2025 (GLOBE NEWSWIRE) — The Descartes Systems Group Inc. (TSX:DSG) (Nasdaq:DSGX) today announced that the Toronto Stock Exchange (the TSX) has accepted Descartes’ notice to launch a Normal Course Issuer Bid (the Bid). Under the Bid, Descartes may repurchase on the open market, at its discretion during the period commencing on December 11, 2025 and ending on the earlier of December 10, 2026 and the completion of purchases under the Bid, up to 8,568,582 common shares, representing approximately 10% of the “public float” (within the meaning of the rules of the TSX), subject to the normal terms and limitations of such bids. Under TSX rules, the average daily trading volume of the common shares on the TSX during the six months ended November 30, 2025 was approximately 204,706...

VIRGINIA CITY, Nev., Dec. 09, 2025 (GLOBE NEWSWIRE) — Comstock Inc. (NYSE: LODE) (“Comstock” and the “Company”) and Comstock Metals LLC (“Comstock Metals”), a leader in the responsible recycling of end-of-life solar panels with the only certified, North American, zero-landfill solution, announced today that Comstock Metals has been recognized for exceptional growth, innovation, workforce excellence, and community partnerships that strengthen and diversify the regional economy. “Comstock has historic and genuine roots in the communities of northern Nevada, and we are honored with EDAWN’s recognition of our continued commitment to innovation, growth and sustainability in the region,” stated Corrado De Gasperis, Comstock’s Executive Chairman and CEO. “Our team’s dedication to excellence, combined with our rapidly growing investments...